HyunHo Jung - Medy Tox CEO Director

086900 Stock  KRW 127,200  4,800  3.64%   

Insider

HyunHo Jung is CEO Director of Medy Tox
Age 61
Phone82 4 3217 1555
Webhttps://www.medy-tox.co.kr

Medy Tox Management Efficiency

The company has return on total asset (ROA) of 0.0304 % which means that it generated a profit of $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.053 %, meaning that it generated $0.053 on every $100 dollars invested by stockholders. Medy Tox's management efficiency ratios could be used to measure how well Medy Tox manages its routine affairs as well as how well it operates its assets and liabilities.
Medy Tox has accumulated 55.38 B in total debt with debt to equity ratio (D/E) of 32.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Medy Tox has a current ratio of 1.01, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Medy Tox until it has trouble settling it off, either with new capital or with free cash flow. So, Medy Tox's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medy Tox sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medy to invest in growth at high rates of return. When we think about Medy Tox's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

INSIDER Age

Lee KooUNISEM Co
61
Kim KyoonUNISEM Co
64
Jungwon WooGenexine
N/A
You SuhGenexine
N/A
Jae ParkGenexine
N/A
JaiHyun KwonGenexine
N/A
Kyu KimGenexine
N/A
Cho BumUNISEM Co
61
Young SungGenexine
67
Sung CPAGenexine
N/A
Sung LeeGenexine
N/A
Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea. Medy Tox (086900) is traded on KOSDAQ in Korea and employs 577 people.

Management Performance

Medy Tox Leadership Team

Elected by the shareholders, the Medy Tox's board of directors comprises two types of representatives: Medy Tox inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medy. The board's role is to monitor Medy Tox's management team and ensure that shareholders' interests are well served. Medy Tox's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medy Tox's outside directors are responsible for providing unbiased perspectives on the board's policies.
HeeSeok Joo, Managing Division
SeungBum Park, Head Director
HyunHo Jung, CEO Director
YongIn Kim, Managing Devel
KiHyuk Yang, MD Laboratory
Lopez Michael, Managing Office
WooSun Lee, Director Department

Medy Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medy Tox a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Medy Tox

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.

Moving together with Medy Stock

  0.86302440 SK BiosciencePairCorr
  0.69054180 MEDICOXPairCorr

Moving against Medy Stock

  0.49317530 CarriesoftPairCorr
  0.4088130 Dong A Eltek SplitPairCorr
The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medy Stock

Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.